Acumen Pharmaceuticals (NASDAQ:ABOS) Announces Quarterly Earnings Results

Acumen Pharmaceuticals (NASDAQ:ABOS) announced its quarterly earnings data on Wednesday. The company reported ($0.45) EPS for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.09), FiscalAI reports.

Here are the key takeaways from Acumen Pharmaceuticals’ conference call:

• Acumen continues to expect top-line Phase II ALTITUDE-AD results in late 2026 for sabirnetug, including clinical efficacy, safety, ARIA rates, and fluid and imaging biomarker data.
• The company nominated two blood-brain-barrier delivery candidates, ACU301 and ACU401, with ACU401 showing up to 40-fold greater frontal-cortex exposure in non-human primates; Acumen expects to file an IND for a lead candidate in mid-2027.
• Management believes sabirnetug’s oligomer selectivity and IgG2 antibody design could provide a differentiated safety and tolerability profile versus plaque-targeting IgG1 therapies, though this remains to be demonstrated in the Phase II readout.
• Acumen ended the quarter with $110.2 million in cash and marketable securities, expected to fund operations only into early 2027, while reporting a second-quarter net loss of $32.7 million.

Acumen Pharmaceuticals Price Performance

Shares of NASDAQ ABOS traded up $0.06 during trading on Wednesday, hitting $2.53. 291,069 shares of the company were exchanged, compared to its average volume of 594,859. The company has a debt-to-equity ratio of 0.19, a current ratio of 4.55 and a quick ratio of 4.55. Acumen Pharmaceuticals has a 1 year low of $1.21 and a 1 year high of $3.60. The company has a market cap of $182.74 million, a price-to-earnings ratio of -1.36 and a beta of 0.36. The firm’s fifty day moving average price is $2.36 and its 200 day moving average price is $2.54.

Insider Activity

In other news, Director Derrell Porter sold 13,040 shares of the stock in a transaction dated Wednesday, June 17th. The shares were sold at an average price of $2.33, for a total value of $30,383.20. Following the completion of the transaction, the director owned 35,500 shares in the company, valued at $82,715. This trade represents a 26.86% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In the last ninety days, insiders have sold 38,700 shares of company stock valued at $89,660. Company insiders own 10.20% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Jane Street Group LLC grew its position in shares of Acumen Pharmaceuticals by 1,526.0% in the second quarter. Jane Street Group LLC now owns 175,670 shares of the company’s stock valued at $204,000 after purchasing an additional 164,866 shares during the last quarter. Marshall Wace LLP purchased a new position in shares of Acumen Pharmaceuticals during the 2nd quarter worth approximately $160,000. Bridgeway Capital Management LLC raised its position in shares of Acumen Pharmaceuticals by 65.1% during the 3rd quarter. Bridgeway Capital Management LLC now owns 190,171 shares of the company’s stock worth $325,000 after purchasing an additional 75,000 shares during the last quarter. Bank of America Corp DE raised its position in shares of Acumen Pharmaceuticals by 45.4% during the 3rd quarter. Bank of America Corp DE now owns 213,729 shares of the company’s stock worth $365,000 after purchasing an additional 66,720 shares during the last quarter. Finally, Hudson Bay Capital Management LP lifted its stake in Acumen Pharmaceuticals by 7.1% in the 2nd quarter. Hudson Bay Capital Management LP now owns 825,004 shares of the company’s stock valued at $957,000 after buying an additional 55,004 shares in the last quarter. 71.01% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on ABOS shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Acumen Pharmaceuticals in a report on Monday, July 6th. Wall Street Zen cut Acumen Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Sunday, July 12th. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $8.00.

About Acumen Pharmaceuticals

Acumen Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of oral small molecule therapies for neurodegenerative diseases. Leveraging a proprietary drug discovery platform that integrates chemoproteomics, high-throughput screening and computational chemistry, the company seeks to identify and optimize compounds that selectively modulate pathological protein aggregation. Its approach is designed to address the underlying biology of conditions such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis and related proteinopathies.

The company’s pipeline comprises multiple lead candidates at various stages of preclinical and early clinical development.